ASTRO Annual Refresher Course registrants have access to additional learning opportunities as discounted registration add-ons.
Registrants who add any of the optional courses below to their registration will be able to access them in the ASTRO Academy until the course(s) expires.
You can add any of the courses below when you register for the 2024 Annual Refresher Course. These courses were originally recorded at the 2023 ASTRO Annual Meeting.
For pricing, visit the registration information page.
Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This course focuses on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing and troubleshooting theranostic delivery. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 are discussed. The course includes didactic presentations from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer segments to discuss practice implementation in various clinical settings (i.e., academic hospital vs. community practice, nuclear medicine vs. radiation oncology). The purpose of this activity is to increase physician, physicist, billing and administration understanding on how to effectively and safely develop a radiopharmaceutical program at their respective institutions. This course was originally recorded at the 2023 ASTRO Annual Meeting.
|
|
|
|---|---|
| Introduction to Radiopharmaceutical Therapies (RPTs) and Basic Radiobiology of RPTs | Ana P. Kiess, MD, PhD |
| Basic Physics and Radiobiology of Radiopharmaceutical Therapies | Stephen A. Graves, PhD, DABR |
| Y90 Radioembolization in the Management of Primary and Metastatic Liver Malignancies | Navesh K. Sharma, DO, PhD, FACRO |
| Evolving Role of PSMA Imaging in the Management of Prostate Cancer | Bridget F. Koontz, MD, FASTRO |
| The Treatment Landscape for mCRPC: Radium 223, Lu-177 PSMA and Future of RLT | William K. Oh, MD |
| Lu-177 PSMA Therapy: Developing the Standard Operating Procedure | Jacqueline Esthappan Zoberi, PhD, DABR, FAAPM |
| Case Presentation and Discussion | Richard Glenn Stock, MD |
| Lu-177-Dotatate (NET): Clinical Indications | Vikas Prasad, MD, PhD |
| Practical Considerations and Post-Therapy Dosimetry for Lu-177 Dotatate | Justin Mikell, PhD, DABR |
| Case Presentation and Discussion | Hyun Kim, MD |
The Palliative Course Package includes two sessions recorded at the 2023 ASTRO Annual Meeting. Both course descriptions and learning objectives appear below.
This activity focuses on the use of whole/near-whole liver radiotherapy for diffuse primary and secondary liver disease, and the use of a variety of radiotherapy treatments for leptomeningeal disease. Common practice patterns for these challenging scenarios are discussed along with available treatment options and strategies for implementing them into practice. The unique challenges associated with treating geriatric patients with advanced cancer are discussed as well.
|
|
|
|---|---|
| Whole/Near-Whole Liver Radiotherapy for Diffuse Primary and Secondary Liver Disease | Said Al Saifi, MD |
| Management Options for Leptomeningeal Disease | Subha Perni, MD |
| The Challenge of Managing Geriatric Patients with Advanced Cancer | Kavita V. Dharmarajan, MD, MSc. |
Palliative radiotherapy (RT) is a foundation of the discipline and practically represents a significant portion of most practices. The standard protocols for palliative RT (8Gy x 1, 4Gy x 5, etc.) were pioneered almost 50 years ago, when systemic therapies were far less useful. Thus, patients may live long enough to recur after RT. Our technology has made image guidance and large doses per fraction very common. Many of us retreat lesions without thinking much about the construct. This could be dangerous. This panel discusses frankly where the data for this practice exist, and where they do not. They also discuss the landmark ESTRO/EORTC consensus document published in October 2022 in Lancet Oncology.
|
|
|
|---|---|
| Retreatment of Bone Metastases for Pain | Edward Chow, MBBS, MSc., PhD, FRCPC |
| Re-irradiation: ESTRO/EORTC Consensus | Peter Hoskin, MD |
| Re-Re-Irradiation (Third Course): Extracranial with Palliative Intent | Emily Keit, MD, BS |
| Retreatment of the Spine and CNS | Dirk Rades, MD, FASTRO |
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a coding update and a scientific overview.
The Practical Radiation Oncology (PRO) Program 2023 includes all PRO sessions originally recorded at the 2023 ASTRO Annual Meeting. Learn more about the presentations and presenters for each PRO session listed below.
This activity provides an in-depth exploration of advanced quantitative imaging techniques for personalized radiotherapy, with a focus on addressing barriers to clinical implementation and improving the management of lung toxicity. Participants are introduced to the latest developments in quantitative imaging modalities, including their applications in radiotherapy treatment planning, response assessment and functional lung avoidance. The activity covers specific use cases in brain and head and neck malignancies, as well as lung cancer radiotherapy. Discussions address quality assurance issues, accessibility, reproducibility, and the integration of artificial intelligence (AI) and automated workflows. The activity reviews state-of-the-art technologies such as SPECT/PET/MR/CT imaging, 4DCT ventilation, Dual Energy CT perfusion, and 4D ventilation/perfusion PET, and their role in optimizing radiotherapy planning while minimizing lung toxicity. Specifically, the technologies reviewed include SPECT/CT imaging, 4DCT ventilation, Dual Energy CT perfusion, and 4D ventilation/perfusion PET. The application of these technologies in defining functional lung volumes and their advantages/disadvantages are reviewed. The applicability and experience of applying these techniques in the radiotherapy workflow for functional lung avoidance are also evaluated. This session was originally recorded during the 2023 ASTRO Annual Meeting.
|
|
|
|---|---|
| Dual Energy CT for Functional Lung Assessment | Houda Bahig, MD, PhD |
| Implementation of Quantitative Imaging Modalities for Brain Tumors to Guide RT Targeting | Hui-Kuo Shu, MD, PhD, FASTRO |
| Ventilation Perfusion PET for Functional Lung Assessment and Avoidance | Nicholas Bucknell, MBBS |
| Development of "Personalized Radiotherapy" Techniques through the Incorporation of Novel Imaging Methodologies | Clifton Fuller, MD, PhD |
| QA Issues with Widespread Implementation of Quantitative Imaging Modalities | Michael Knopp, MD, PhD |
Questions? Contact ASTRO eLearning.
